CANCERS BRONCHIQUES NON A PETITES CELLULES AU STADE AVANCE
|
|
|
référence |
chimiothérapie |
n |
(stIV) |
% RO |
p |
SM |
p |
|
Georgoulias, 2001 (1) |
I. CDDP (80 mg/m²)+docetaxel (100 mg/m²) |
205 |
(129) |
35 |
NS |
|
NS |
|
II. Gemci + docetaxel (100 mg/m²) |
201 |
(130) |
33 |
|
|||
|
Schiller, 2002 (2) |
I.CDDP (75 mg/m²)+
paclitaxel (135 mg/m²) |
303 |
89 |
21 |
NS |
|
NS |
|
II.CDDP 100 +
gemcitabine |
301 |
86 |
22 |
|
|||
|
III.CDDP 75 + docetaxel
(75 mg/m²) |
304 |
86 |
17 |
|
|||
|
IV.Carboplatine (AUC 6) + paclitaxel (225) |
299 |
86 |
17 |
|
|||
|
Perol, 2002 (3) |
I. docetaxel
(100)~CDDP-VNR |
38 |
tous |
11 |
|
29 s |
|
|
II. CDDP-VNR |
32 |
25 |
43 s |
||||
|
Fossella, 2003 (4) |
I. Docétaxel + CDDP (75) |
408 |
67 % |
32 |
S |
|
0,044 * |
|
II. Docétaxel +
Carboplatine (AUC 6) |
404 |
67 % |
24 |
|
|||
|
III. CDDP (100) + VNR |
404 |
67 % |
24,5 |
|
|||
|
Kubota, 2004 (5) |
I. Docétaxel (60) + CDDP
(80) |
151 |
tous |
37% |
S |
|
0,014 |
|
II. VDS + CDDP (80) |
151 |
21% |
|
||||
|
Rocha-Lima, 2004 (6) |
I.
gemcitabine + irinotecan |
39 |
(30) |
12,8 % |
|
|
|
|
II.
gemcitabine + docétaxel |
39 |
(31) |
23,1 % |
|
|
|
|
|
Yamamoto, 2004 (7) |
I. CDDP (80) + docetaxel
(60) |
51 |
(40) |
37 % |
NS |
50 s |
NS |
|
II.
Irinotecan + docetaxel (60) |
57 |
(43) |
32 % |
46 s |
|||
|
Georgoulias, 2004 (8) |
I.
Docetaxel (100) |
152 |
64% |
15 % |
0,004 |
|
0,2 |
|
II.
Docetaxel (100) + cisplatin (80 J2) |
167 |
65% |
36 % |
|
|||
|
Douillard, 2005 (9) |
I.
docétaxel (75) + cisplatine (100) |
115 |
100% |
34% |
0,20 |
8m |
NS |
|
II.
vinorelbine + cisplatine (100) |
118 |
100% |
26% |
9m |
|||
|
Booton, 2006 (10;11) |
I.
docétaxel (75) + carboplatine (AUC 6) |
217 |
48 % |
32 % |
NS |
|
0.29 |
|
II.
MMC + CDDP (50) + Ifo or VBL |
216 |
53 % |
32 % |
|
|||
|
Kudoh, 2006 (11) |
I. Docetaxel (60) |
69 |
63 % |
23 % |
0.02 |
|
0,065 |
|
II.
Vinorelbine (> ou = 70 ans) |
91 |
64 % |
10 % |
|
|||
|
Park, 2007 (12) |
I.
CDDP (75) + docétaxel (35/sem) |
44 |
(33) |
39 % |
NS |
|
NS |
|
II.
CDDP (75) + docétaxel (75/ 3 sem) |
42 |
(30) |
40 % |
|
|||
|
Lilenbaum, 2007 (13) |
I.
Docétaxel 75 / 3 sem |
55 |
85 % |
9,1 % |
NS |
|
NS |
|
II.
Docétaxel 30 / sem |
56 |
82 % |
5,4 % |
|
|||
|
Leong, 2007 (14) |
I.
Gemcitabine 800/sem |
43 |
(34) |
16 % |
NS |
|
|
|
II.
Vinorelbine 25/sem |
45 |
(35) |
20 % |
|
|||
|
III.
Docétaxel 30/sem |
46 |
(34) |
22 % |
|
|||
|
Chen, 2007 (15) |
I.
CDDP (60) + docetaxel |
46 |
80 % |
44 % |
NS |
|
NS |
|
II.
CDDP (60) + vinorelbine |
48 |
83 % |
46 % |
|
|||
|
Georgoulias, 2008 (16) |
I.
Docétaxel (100) |
155 |
77 % |
12 % |
S |
|
0,037 |
|
II.
Docétaxel (75) + gemcitabine |
157 |
77 % |
27 % |
|
|||
|
Hainsworth, 2007 (17) |
I.
Docétaxel (hebd) |
171 |
73 % |
17 % |
0,1 |
|
0,65 |
|
II.
Docétaxel + gemcitabine |
174 |
76 % |
25 % |
|
|||
|
Kim, 2012 (18) |
I.
Docétaxel 75 + cisplatine 60 |
65 |
59 |
43 % |
NS |
|
NS |
|
I.
Docétaxel 60 + cisplatine 60 |
67 |
60 |
44 % |
13 ,6m |
* comparaison ajustée
Références
(1) Georgoulias V, Papadakis E, Alexopoulos A, Tsiafaki X, Rapti A, Veslemes M et al. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet 2001; 357(9267):1478-1484.
(2) Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346(2):92-98.
(3) Perol M, Lena H, Thomas P, Robinet G, Fournel P, Coste E et al. Phase II randomized multicenter study evaluating a treatment regimen alternating docetaxel and cisplatin-vinorelbine with a cisplatin-vinorelbine control group in patients with stage IV non-small-cell lung cancer: GFPC 97.01 study. Ann Oncol 2002; 13(5):742-747.
(4) Fossella F, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003; 21(16):3016-3024.
(5) Kubota K, Watanabe K, Kunitoh H, Noda K, Ichinose Y, Katakami N et al. Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. J Clin Oncol 2004; 22(2):254-261
(6) Rocha Lima CM, Rizvi NA, Zhang C, Herndon JE, Crawford J, Govindan R et al. Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC. Ann Oncol 2004; 15(3):410-418.
(7) Yamamoto N, Fukuoka M, Negoro SI, Nakagawa K, Saito H, Matsui K et al. Randomised phase II study of docetaxel/cisplatin vs docetaxel/irinotecan in advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group Study (WJTOG9803). Br J Cancer 2004; 90(1):87-92.
(8) Georgoulias V, Ardavanis A, Agelidou A, Agelidou M, Chandrinos V, Tsaroucha E et al. Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer: a randomized, multicenter phase III trial. J Clin Oncol 2004; 22(13):2602-2609.
(9) Douillard JY, Gervais R, Dabouis G, Le Groumellec A, D'Arlhac M, Spaeth D et al. Sequential two-line strategy for stage IV non-small-cell lung cancer: docetaxel-cisplatin versus vinorelbine-cisplatin followed by cross-over to single-agent docetaxel or vinorelbine at progression: final results of a randomised phase II study. Ann Oncol 2005; 16(1):81-89.
(10) Booton R, Lorigan P, Anderson H, Baka S, Ashcroft L, Nicolson M et al. A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1). Ann Oncol 2006; 17(7):1111-1119.
(11) Kudoh S, Takeda K, Nakagawa K, Takada M, Katakami N, Matsui K et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol 2006; 24(22):3657-3663.
12) Park SH, Choi SJ, Kyung SY, An CH, Lee SP, Park JW, et al. Randomized phase II trial of two different schedules of docetaxel plus cisplatin as first-line therapy in advanced nonsmall cell lung cancer. Cancer 2007 Feb 15;109(4):732-40.
(13) Lilenbaum R, Rubin M, Samuel J, Boros L, Chidiac T, Seigel L, et al. A randomized phase II trial of two schedules of docetaxel in elderly or poor performance status patients with advanced non-small cell lung cancer. J Thorac Oncol 2007 Apr;2(4):306-11.
(14) Leong SS, Toh CK, Lim WT, Lin X, Tan SB, Poon D, et al. A randomized phase II trial of single-agent gemcitabine, vinorelbine, or docetaxel in patients with advanced non-small cell lung cancer who have poor performance status and/or are elderly. J Thorac Oncol 2007 Mar;2(3):230-6.
(15) Chen YM, Perng RP, Shih JF, Tsai CM, Whang-Peng J. A randomized phase II study of docetaxel or vinorelbine in combination with cisplatin against inoperable, chemo-naive non-small-cell lung cancer in Taiwan. Lung Cancer 2007 Jun;56(3):363-9.
(16) Georgoulias V, Androulakis N, Kotsakis A, Hatzidaki D, Syrigos K, Polyzos A, et al. Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: a randomized, multicenter phase III trial. Lung Cancer 2008 Jan;59(1):57-63.
(17) Hainsworth JD, Spigel DR, Farley C, Shipley DL, Bearden JD, Gandhi J, et al. Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer: a randomized phase 3 trial of the Minnie Pearl Cancer Research Network. Cancer 2007 Nov 1;110(9):2027-34.
(18) Kim KS, Oh IJ, Ban HJ, Cho HJ, Kwon YS, Kim YI, et al. Comparison of docetaxel/cisplatin dosages of 75/60 and 60/60 mg/m(2) for the treatment of non-small cell lung cancer. Exp Ther Med 2012 Aug;4(2):317-22.